1. Show article details.

    ZELTIQ Announces Conference Call and Webcast of First Quarter 2014 Financial Results to Be Held on April 29, 2014

    Market Wire – 4:05 PM ET 04/15/2014

    04/15/14 -- ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today that it plans to release its first quarter 2014 financial results on Tuesday, April 29, 2014 after the market close.

  2. Show article details.

    Relief for "Thigh Shy" Consumers: CoolSculpting(R) Receives FDA Clearance for Non-Surgical Reduction of Thigh Fat

    Market Wire – 8:30 AM ET 04/14/2014

    04/14/14 -- ZELTIQ® Aesthetics, Inc., a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology, today announced that the CoolSculpting procedure has received U.S. Food and Drug Administration clearance to treat the thighs with its entire suite of applicators.

  3. Show article details.

    ZELTIQ Announces FDA Clearance to Treat Thighs

    Market Wire – 8:30 AM ET 04/14/2014

    04/14/14 -- ZELTIQ Aesthetics, Inc. (ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology, today announced it has received U.S. Food and Drug Administration clearance to treat the thigh area with its entire suite of applicators.

  4. Show article details.

    Financial Results Schedules, Approvals, Appointments, Product Launches, and Stock Movements - Analyst Notes on Allergan, Accuray, Cerus, Galena Biopharma, and ZELTIQ Aesthetic

    PR Newswire – 8:00 AM ET 04/09/2014

    NEW YORK, April 9, 2014 Today, Analysts Review released its analysts' notes regarding Allergan Inc. (AGN), Accuray Incorporated (ARAY), Cerus Corporation (CERS), Galena Biopharma, Inc. (GALE), and ZELTIQ Aesthetics, Inc. (ZLTQ). Private wealth members receive these notes ahead of publication.

  5. Show article details.

    CoolSculpting(R) Procedure Achieves Strong Podium Presence at ASLMS 2014

    Market Wire – 8:00 AM ET 04/03/2014

    04/03/14 -- ZELTIQ® Aesthetics, Inc., a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced its CoolSculpting procedure, a non-surgical, clinically proven procedure designed to selectively reduce fat in treated areas using a patented cooling technology, will be featured in 10 podium pres...

  6. Show article details.

    Farewell Thunder Thighs, So Long Saddlebags: ZELTIQ(R) Aesthetics Launches Non-Surgical Solution to Significantly Reduce Fat on Outer Thighs

    Market Wire – 2:00 AM ET 04/03/2014

    04/03/14 -- Visionary medical device company ZELTIQ Aesthetics, Inc. (ZLTQ), has launched the CoolSmooth™ applicator, the first and only non-surgical solution designed to reduce fat on the outer thighs, with a comfortable design that adjusts to fit each unique patient.

  7. Show article details.

    ZELTIQ(R) Aesthetics Launches CoolSmooth(TM) Applicator

    Market Wire – 8:00 AM ET 03/21/2014

    03/21/14 -- ZELTIQ Aesthetics, Inc. (ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology, today announced the global introduction of the CoolSmooth applicator, the latest addition to the applicator platform for the CoolSculpting system, at the American Academy of Dermatology, annual meeting in Denver, Colo.

  8. Show article details.

    ZELTIQ to Present at 26th Annual ROTH Conference

    Market Wire – 4:05 PM ET 02/26/2014

    02/26/14 -- ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Mark Foley, President and Chief Executive Officer, and Patrick F. Williams, Senior Vice President and Chief Financial Officer, are scheduled to present at the 26th Annual ROTH Conference at the Ritz Carlton in...

  9. Show article details.

    ZELTIQ Aesthetics Announces Fourth Quarter and Full Year 2013 Financial Results

    Market Wire – 4:00 PM ET 02/25/2014

    02/25/14 -- ZELTIQ® ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced financial results for the fourth quarter and full year ended December 31, 2013.

  10. Show article details.

    ZELTIQ Announces Conference Call and Webcast of Fourth Quarter and Full Year 2013 Financial Results to be Held on February 25, 2014

    Market Wire – 4:05 PM ET 02/10/2014

    02/10/14 -- ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today that it plans to release its fourth quarter and full year 2013 financial results on Tuesday, February 25, 2013 after the market close.

  11. Show article details.

    ZELTIQ to Present at Leerink Global Healthcare Conference

    GlobeNewswire – 4:18 PM ET 02/03/2014

    ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Mark Foley, President and Chief Executive Officer, and Patrick F. Williams, Chief Financial Officer, are scheduled to present at the Leerink Global Healthcare Conference at the Waldorf Astoria in New York City.

  12. Show article details.

    ZELTIQ(R) Aesthetics to Exhibit at IMCAS 2014

    Market Wire – 1:00 AM ET 01/31/2014

    01/31/14 -- ZELTIQ Aesthetics, Inc. (ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced it is showcasing its CoolSculpting system at the International Master Course on Aging Skin Annual Meeting in Paris, 31 January to 2 February, 2014.

  13. Show article details.

    ZELTIQ Reports Preliminary Fourth Quarter and Full Year 2013 Revenue

    GlobeNewswire – 8:00 AM ET 01/13/2014

    Ships 1,000,000th CoolSculpting® Cycle Announces New CoolSmooth™ Applicator PLEASANTON, Calif., Jan. 13, 2014 -- ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today preliminary unaudited revenue for the fourth quarter and full year 2013.

  14. Show article details.

    ZELTIQ to Present at J.P. Morgan Healthcare Conference

    GlobeNewswire – 8:30 AM ET 01/06/2014

    ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Mark Foley, President and Chief Executive Officer, is scheduled to present at the 32nd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco. Event:  J.P. Morgan Healthcare Conference.

  15. Show article details.

    Versartis Appoints Joshua T. Brumm as Chief Financial Officer

    Market Wire – 8:00 AM ET 12/16/2013

    12/16/13 -- Versartis, Inc. today announced the expansion of its management team with the appointment of Joshua T. Brumm as its first Chief Financial Officer. "Josh has a strong track record of building successful companies and building great finance teams," commented Dr. Cleland.

  16. Show article details.

    ZELTIQ to Present at J.P. Morgan SMid Cap Conference

    GlobeNewswire – 8:30 AM ET 12/02/2013

    ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Patrick F. Williams, Senior Vice President and Chief Financial Officer, is scheduled to present at the J.P. Morgan SMid Cap Conference at The Westin River North in Chicago.

  17. Show article details.

    ZELTIQ Aesthetics, Inc. Announces Pricing of Public Offering of Common Stock

    GlobeNewswire – 9:06 PM ET 11/07/2013

    ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today that it has priced an underwritten public offering of 4,500,000 shares of its common stock, all of which are being offered by selling stockholders, at a price to the public of $13.00 per share.

  18. Show article details.

    ZELTIQ Aesthetics, Inc. Announces Proposed Public Offering of Common Stock

    GlobeNewswire – 4:01 PM ET 11/05/2013

    ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today the commencement of an underwritten public offering of 4,500,000 shares of its common stock, all of which are being offered by selling stockholders.

  19. Show article details.

    ZELTIQ to Present at Canaccord Genuity Medical Technology and Diagnostics Forum

    GlobeNewswire – 4:05 PM ET 10/31/2013

    ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Mark Foley, President and Chief Executive Officer and Patrick F. Williams, Senior Vice President and Chief Financial Officer, are scheduled to present at the Canaccord Genuity Medical Technology and Diagnostics Forum at T...

  20. Show article details.

    ZELTIQ Announces Third Quarter 2013 Financial Results

    GlobeNewswire – 4:01 PM ET 10/30/2013

    Raises 2013 Financial Guidance PLEASANTON, Calif., Oct. 30, 2013 -- ZELTIQ®, a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced financial results for the third quarter 2013.

Page:

Today's and Upcoming Events

  • Apr
    29

    ZLTQ to announce Q1 earnings After Market (Confirmed)

  • Apr
    29

    ZLTQ Earnings Conference Call at 4:30 PM Listen

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2014

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.